Award details

Efficient and specific tumour cell killing by apoptin linked to VP22

Reference	GTH12530
Principal Investigator / Supervisor	Professor Mahvash Tavassoli
Co-Investigators / Co-Supervisors	Professor Farzin Farzaneh, Dr Joop Gaken
Institution	King's College London
Department	Department of Molecular Medicine
Funding type	Research
Value (£)	159,248
Status	Completed
Type	Research Grant
Start date	01/10/2000
End date	01/10/2003
Duration	36 months

Abstract

The essential prerequisites for cancer gene therapy are efficient gene delivery and tumour cell specificity. In addition, the induction of a bystander effect is crucial for complete eradication of both primary and metastatic tumours. So far the available vectors and systems for gene therapy lack at least one of these essential features. We are proposing to combine the unique and important properties of two proteins; apoptin which has the unique feature of tumour specific induction of apoptosis, and VP22 which is able to traffic between cells even when fused to other proteins. Expression of fusion proteins of apoptin and VP22 will result in tumour specific killing (due to apoptin) and induction of a strong bystander effect (due to the VP22 moiety). For efficient in vitro and in vivo delivery VP22-apoptin fusion will be cloned into both retro and adenoviral vectors.

Summary

unavailable

Committee	Closed Committee - Genes & Developmental Biology (GDB)
Research Topics	X – not assigned to a current Research Topic
Research Priority	X – Research Priority information not available
Research Initiative	Gene Technologies Underpinning Healthcare (GTH) [1999]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search